Pharmaceutical

STAT+: A single drug and multiple study failures leave Anavex with nothing but cash

STAT+: A single drug and multiple study failures leave ...

Jan 2, 2024

It took Anavex Life Sciences seven months to finally acknowledge the failure of ...

STAT+: LabCentral, a crucial Boston incubator for drug discovery, is slated to grow amid industry slowdown

STAT+: LabCentral, a crucial Boston incubator for drug ...

Jan 2, 2024

Biotech incubator LabCentral has expanded rapidly amid fluctuating vacancy rates...

UnitedHealth’s rehab restrictions, Texas medical school drama, and health care’s biggest profits

UnitedHealth’s rehab restrictions, Texas medical school...

Jan 2, 2024

The latest edition of STAT's Health Care Inc. newsletter touches on UnitedHealth...

An ugly fight over care for the poor in Texas

An ugly fight over care for the poor in Texas

Jan 2, 2024

Read this week's edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about...

STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles

STAT+: Pharmalittle: Drugmakers raise prices, pharmacie...

Jan 2, 2024

Drugmakers plan to raise prices in the United States on more than 500 drugs in e...

STAT+: Here’s who’s profiting the most in health care

STAT+: Here’s who’s profiting the most in health care

Jan 2, 2024

Ahead of the dealmaking & hobnobbing of #JPM2024, STAT took a look at which #hea...

STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch

STAT+: The biotech scorecard for the first quarter: 17 ...

Jan 2, 2024

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech eve...

STAT+: It was a turbulent year for the business of health tech. 3 trends to watch in 2024

STAT+: It was a turbulent year for the business of heal...

Jan 2, 2024

In 2023, selling tech-enabled health care services was slow and hard, even for s...

STAT+: Texas taxpayers wanted to help the poor get health care. Instead, they’re funding a medical school at a wealthy university

STAT+: Texas taxpayers wanted to help the poor get heal...

Jan 2, 2024

Texas taxpayers wanted to help the poor get health care. Instead, they’re fundin...

STAT+: Inside Ascension’s legal fight with a Texas agency over caring for the poor

STAT+: Inside Ascension’s legal fight with a Texas agen...

Jan 2, 2024

Ascension is locked in a legal battle with an Austin, Texas, agency over whether...

FDA warns of rare hypersensitivity reaction due to antiseizure drugs

FDA warns of rare hypersensitivity reaction due to anti...

Dec 30, 2023

FDA warns that levetiracetam and clobazam can cause DRESS, a rare hypersensitivi...

Enveric’s EB-003 selected as lead candidate for mental health disorders

Enveric’s EB-003 selected as lead candidate for mental ...

Dec 30, 2023

Enveric Biosciences has selected EB-003 as its lead drug candidate from its EVM3...

Opinion: Buprenorphine, autism diagnoses, and long Covid: the most-read First Opinion essays of 2023

Opinion: Buprenorphine, autism diagnoses, and long Covi...

Dec 29, 2023

Prescribing buprenorphine, autism diagnosis, and long Covid: the most-read First...

Opinion: There’s a less intimidating alternative to EpiPens for dangerous allergic reactions. Why won’t the FDA approve it?

Opinion: There’s a less intimidating alternative to Epi...

Dec 29, 2023

There’s a less intimidating alternative to EpiPens for dangerous allergic reacti...

Fights over methadone, harm reduction, and more: 3 addiction stories to watch in 2024

Fights over methadone, harm reduction, and more: 3 addi...

Dec 29, 2023

Harm reduction for opioid addiction had been gaining ground. The next year will ...

We wish we’d written that: STAT staffers share their favorite stories of 2023

We wish we’d written that: STAT staffers share their fa...

Dec 29, 2023

STAT staffers are sharing their favorite stories of 2023 — that they wish they h...